The NeurologyLive® epilepsy clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to epilepsy and related epileptic conditions, including Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, focal seizures, nonmotor seizures, and more.
May 12th 2024
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on cluster headache.
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Adjusting Antiseizure Medication Dosages Improves Retention of Cenobamate
December 2nd 2023In a recent post hoc analysis of the Study C021 trial, findings support the idea that early adjustments to concomitant antiseizure medications enhance the retention of cenobamate, an FDA-approved treatment for focal seizures.
A Paradigm Shift in Preventing Drug-Resistant Epilepsy: Pavel Klein, MD
December 1st 2023The director of the Mid-Atlantic Epilepsy & Sleep Center and adjunct associate professor of neurology at George Washington University discussed the advancements in epilepsy research, especially for drug-resistant epilepsy, to be presented at AES 2023. [WATCH TIME: 4 minutes]
Exploring the Hidden Burdens of Persistent Seizures for Patients: Danielle Becker, MD, MS, FAES
December 1st 2023The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center discussed the profound repercussion of ongoing seizures for patients with epilepsy which is to be presented at AES 2023 in SK Life Science’s symposium. [WATCH TIME: 5 minutes]
FDA Warns of Serious Adverse Effects for Using Levetiracetam and Clobazam in Epilepsy
November 28th 2023In a new announcement, the FDA warns patients to immediately seek out medical attention if unexplained rash, fever, or swollen lymph nodes develop when using the antiseizure medications levetiracetam and clobazam.
New Frontiers in the Prevention of Seizures, Gene Therapy in Epilepsy: William Gallentine, DO
November 28th 2023The interim chief of pediatric neurology at Stanford Medicine Children’s Health discussed progress in preventing seizures among patients with epilepsy, the potential for gene-targeted therapies, and the importance of localizing where seizures are coming from. [WATCH TIME: 5 minutes]
NRTX-1001 Shows Seizure Suppression in Preclinical Drug-Resistant Focal Epilepsy Models
November 27th 2023Neurona Therapeutics’ NRTX-1001, a regenerative neural cell therapy derived from human stem cells, showed promise in potentially suppressing seizures in patients with drug-resistant mesial temporal lobe epilepsy.
Study Reveals Association Between Amygdala Region and Persistent Breathing Loss Following Seizures
November 22nd 2023In a recently published study, investigators have identified a part of the brain that may be associated with breathing failure following a seizure in patients with severe epilepsy that cannot be managed with treatment.
Effectiveness of Midazolam for Seizure Cluster Management: Kamil Detyniecki, MD
November 21st 2023The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes]
Identifying the Right Candidate for Epilepsy Surgery: William Gallentine, DO
November 20th 2023The interim chief of pediatric neurology at Stanford Medicine Children’s Health provided insight on advances the screening for epilepsy surgery and the factors that pediatric neurologists should consider. [WATCH TIME: 5 minutes]
Intermittent Use of Midazolam Shows Continued Favorable Profile in Seizure Clusters
November 16th 2023In a recent post hoc analysis, findings showed that nearly 50% of patients treated with 1 or 2 doses of midazolam experienced return to full baseline functionality in 1 hour of administration.